iBio (IBIO) Q2 2026 earnings summary

Executive summary

• Focused on preclinical development of AI-driven precision antibodies for cardiometabolic and obesity indications, with IBIO-600 and IBIO-610 expected to enter clinical trials in 2026 and 2027, supported by new data and scientific presentations.

• Strategic collaborations, notably with AstralBio, have expanded the pipeline and provided exclusive licenses for key assets.

• Secured $26 million in PIPE financing, extending cash runway into Q3 FY2028.

• The company is actively seeking partners for certain assets and out-licensing opportunities to maximize value and accelerate development.

Financial highlights

• Net loss for the quarter ended December 31, 2025 was $9.0 million ($0.09 per share), compared to $4.4 million ($0.48 per share) in the prior year period.

• Net loss for the six months ended December 31, 2025 was $14.7 million ($0.19 per share), up from $8.4 million ($0.94 per share) year-over-year.

• Total operating expenses for the quarter were $9.4 million, up from $4.6 million in the prior year, driven by increased R&D and a $2.5 million impairment charge.

• Cash, cash equivalents, and investments totaled $52.7 million as of December 31, 2025.

• R&D expenses increased to $4.3 million from $1.9 million year-over-year, and G&A expenses rose to $5.2 million from $2.7 million, mainly due to impairment of an intangible asset.

Outlook and guidance

• IBIO-610 is on track for first human clinical trials in early 2027; IBIO-600 expected to enter Phase 1a trials in the first half of 2026.

• Current cash, cash equivalents, and investments, plus $26 million raised in January 2026, are expected to fund operations into Q3 fiscal 2028.

• No significant revenue is expected for several years; focus remains on advancing the pipeline and seeking partnerships.